Biogen (BIIB) Underpromise/Overdeliver Strategy Plays Well on Wall Street

July 25, 2013 10:55 AM

Leerink Swann today maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $271. Biogen reported strong ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found